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BacŬgƌŽƵŶd: The human immunodeficiency virus (HIV)-related wasting syndrome (WS) identifies the
body composition changes commonly affecting the HIV population under highly active antiretroviral
therapy (HAART). WS remains a relevant medical problem in HIV-infected patients, considering its
relationship with metabolic complications, disease progression, premature aging and impaired survival.
Anabolic  properties  characterizing  testosterone (T)  or  T-derived analogues  made the androgen-
supplementation an attractive therapeutic option at preventing WS in this population, although a clear
demonstration of its beneficial effect is not achieved so far.
Aŝŵ Žf ƚŚe ƐƚƵdǇ: This meta-analysis was designed to comprehensively evaluate the effectiveness and
safety of T and others androgenic therapy in HIV setting, focusing on male patients.
MeƚŚŽdƐ:  All  randomized,  controlled clinical  trials  evaluating androgens administration on body
compositions parameters comparing HIV androgens-treated men vs HIV-untreated or healthy untreated
controls were considered eligible. To highlight the efficacy of androgens administration, total and free T
serum levels were further analysed, and the treatment safety was evaluated considering the dropout
and the adverse events rates.
ReƐƵůƚƐ: Twenty-one studies were included, comparing ϲϲϭ HIV androgen-treated and ϲϬϲ placebo-
treated men. A significant increase in body weight was depicted in T-treated men (pсϬ.ϬϬϴ). The same
beneficial  effect  was  observed considering lean body mass  (pфϬ.ϬϬϭ)  and fat-free mass  changes
(pфϬ.ϬϬϭ), independently from the androgen molecule used (T or Nandrolone). No differences were
found considering fat mass and body mass cell. Both total (pфϬ.ϬϬϭ) and free (pфϬ.ϬϬϭ) T serum levels
increased after T use, rather than androgen-related molecules, associated with a significant decrease of
sex hormone binding globulin levels (pфϬ.ϬϬϭ). The adverse events rate was higher in androgen-treated
compared to controls (pсϬ.ϬϮϬ).
CŽŶcůƵƐŝŽŶ:  The androgenic treatment for anabolic purposes in HIV male patients leads to a mild
improvement of some body composition parameters, although not predictable. Considering the general
frailty of HIV patients and the significant adverse effects burden characterizing the anabolic androgen
therapy, a personalized and tailored therapeutic approach remains more than ever mandatory in such
patients.
